REG - Poolbeg Pharma PLC - Termination of proposed combination with HOOKIPA

Poolbeg PharmaAnnouncement

21/02/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250221:nRSU9431Xa&default-theme=true

RNS Number : 9431X  Poolbeg Pharma PLC  21 February 2025

21 February 2025

 

 

Poolbeg Pharma plc

 

Termination of proposed combination with HOOKIPA Pharma Inc.

 

Further to the 2.4 announcement on 2 January 2025 on the potential combination
of Poolbeg Pharma ("Poolbeg" or the "Company") and HOOKIPA Pharma Inc
("HOOKIPA"), the Board of Poolbeg announces that it was informed yesterday
that HOOKIPA has terminated discussions on the proposed combination of the two
companies.

 

Cathal Friel, Executive Chairman of Poolbeg, said: "We were surprised and
disappointed to hear of HOOKIPA's decision to withdraw from the combination
discussions. Throughout this process, we have seen strong interest in the
potential of POLB 001 and we continue to be focused on maximising the
potential of our in-house programmes and exploring new opportunities to
generate value for our shareholders."

 

ENDS

 

 

 Enquiries:
 Poolbeg Pharma Plc                                                          +44 (0) 207 183 1499
 Cathal Friel, Chairman                                                      ir@Poolbegpharma.com
 Jeremy Skillington, CEO
 Ian O'Connell, CFO

 Cavendish Capital Markets Ltd                                               +44 (0) 207 220 0500

 (Joint Financial Adviser and Rule 3 Adviser to Poolbeg, NOMAD & Joint
 Broker)
 Corporate Finance

 Geoff Nash

 Henrik Persson

 Hamish Waller

 Trisyia Jamaludin
 Shore Capital                                                               +44 (0) 207 408 4090

 (Joint Broker)
 Corporate Advisory

 David Coaten

 Harry Davies-Ball
 Corporate Broking

 Malachy McEntyre

 Isobel Jones

 J&E Davy                                                                    +353 (0) 1 679 6363

 (Joint Broker)
 Anthony Farrell
 Niall Gilchrist

 Optimum Strategic Communications                                            +44 (0) 208 078 4357
 Nick Bastin                                                                 Poolbeg@optimumcomms.com
 Vici Rabbetts
 Elena Bates

 

About Poolbeg Pharma plc

Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focussed on
acquiring, developing and commercialising innovative medicines that will help
improve the lives of patients with rare and orphan diseases and where there is
a high unmet medical need. Poolbeg comprises a strong and growing portfolio of
development assets. For more information, please go to www.poolbegpharma.com
(https://www.poolbegpharma.com/)  or follow us on Twitter
(https://twitter.com/PoolbegPharma/)  and LinkedIn
(https://www.linkedin.com/company/poolbeg-pharma/)  @PoolbegPharma.

 

Forward-Looking Statements

This announcement may contain forward-looking statements and the words
"expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast",
"project" and similar expressions (or their negative) identify certain of
these forward-looking statements. The forward-looking statements in this
announcement are based on numerous assumptions and Poolbeg's present and
future business strategies and the environment in which Poolbeg expects to
operate in the future. Forward-looking statements involve inherent known and
unknown risks, uncertainties and contingencies because they relate to events
and depend on circumstances that may or may not occur in the future and may
cause the actual results, performance or achievements to be materially
different from those expressed or implied by such forward-looking statements.
These statements are not guarantees of future performance or the ability to
identify and consummate investments. Many of these risks and uncertainties
relate to factors that are beyond Poolbeg's ability to control or estimate
precisely, such as future market conditions, currency fluctuations, the
behaviour of other market participants, the outcome of clinical trials, the
actions of regulators and other factors such as Poolbeg's ability to obtain
financing, changes in the political, social and regulatory framework in which
Poolbeg operates or in economic, technological or consumer trends or
conditions. Past performance should not be taken as an indication or guarantee
of future results, and no representation or warranty, express or implied, is
made regarding future performance. No person is under any obligation to update
or keep current the information contained in this announcement or to provide
the recipient of it with access to any additional relevant information.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  SOAFZGZZGGFGKZZ